Antitumor effects and function of T cells in tumor bearing mice given conagenin (CNG), a low molecular immunomodulator,were investigated. The administration of CNG,once a week for 4 weeks, was the most effective schedule in inhibiting growth of IMCcarcinoma, a syngeneic tumor. In this regimen, cytotoxic T lymphocytes and natural killer activities in spleens of CNGtreated mice were maintained at higher levels than those of non-treated mice. Lymphokine production by splenic T cells was also enhanced in cultures, whereas monokineproduction by macrophages, which was increased in accordance with tumor growth, was reduced by CNGadministration.
It is known that immunomodulators such as ubenimex1*, forphenicinol2) and MDP3) stimulate T cells through activation of macrophages. They have shown antitumor effects on murine transplantable tumor models4~7). Polysaccharides such as lentinan8~10), sizofilan1 1'12) and PS-K13) activate macrophages and T cells. However, it can be considered that the activation of macrophages induces non-specific augmentation in the host immunesystem, and high molecular substances such as /?-glucan and LPScan show side-effects by their inflammatory activities.
Thus, we have sought immunomodulatorswhich act on activated T cells exclusively and found conagenin (CNG), a low molecular immunomodulator, in cultured broth of Streptomyces roseosporus1^. In this paper, we report antitumor effects of CNGand modulation of T cell functions in tumor bearing mice given CNG.
Materials and Methods

Mice
CDFXmice, 6 weeks old, were purchased from Charles River Japan Inc. (Kanagawa, Japan), and were maintained under specific pathogen-free conditions at 23± 1°C and 55+5% humidity. BALB/c nu/nu(-) mice, 6 weeks old, purchased from Japan SLC Inc. (Shizuoka, Japan), were kept in a clean rack with the above conditions. These mice were employed for experiments at 9~1 1 weeks of age.
Conagenin
Conagenin (CNG) was prepared according to the procedures reported14) by KANEKA Co. Ltd. (Osaka, Japan). For experiments, CNGwas dissolved in sterilized saline. IMCcarcinoma cells were maintained in CDF1mice by weekly intraperitoneal transfer. Cells (1 x 106 cells) were inoculated sc to the inguinal region of CDFXmice. CNGwas administered ip on various schedules starting at day 1 after tumor inoculation. Antitumor activity was determined by measuring tumor volume (mm3) at weekly intervals and by weighing at day 35 after the inoculation. The tumor volume was determined by the following formula: Tumorvalume(mm3)= length(mm) x width(mm)2 x 0.5. The percentage of inhibition of tumor weight was calculated as follows: Inhibition(%)
Meantumor weight of treated group Meantumor weight of control group ) x lOO.
Antitumor activity of CNGin immunocompromisedmice was also tested. CDF1mice were injected with 5/vl of anti-asialo GM1 serum (Wako Chemicals Co., Ltd., Tokyo, Japan) 2 days before, and 4, 10 and 16 days after inoculation of IMCcarcinoma cells. These mice were inoculated sc with 1 x 106 IMC carcinoma cells and given CNGonce a week for 4 weeks starting at day 1 after tumor inoculation.
In another experiment, BALB/cnu/nu(-) mice were inoculated sc with 5 x 105 IMCcarcinoma cells and were given CNG on the sameschedule as above.
Cytotoxic T Lymphocytes and Natural Killer Activities
Cytotoxic T lymphocyte (CTL) activity in splenic T cells and natural killer (NK) activity in unfractionated spleen cells prepared from CDFXmice were determined against IMCcarcinoma cells and YAC-1cells, respectively. Nylon wool-passed spleen cells were used as T cells. 51Cr (Na251CrO4, sp.act. 14.3 GBq/mg, NEZ-030, New England Nuclear, Boston, U.S.A.) labeled IMC carcinoma cells and YAC-1 cells (2 x 105 cells/ml) were incubated with effector cells at ratios of 100 : 1 for 16 and 4 hours, respectively. After incubation, the supernatants were collected and 5 1Cr radioactivity was counted in a gammacounter (ARC-300, ALOKA,Tokyo, Japan). After disruption by 1% SDS the maximum counts in target cells were determined. Triplicate determinations were made. The meanpercentage of specific cytotoxicity was calculated as follows: %cytotoxicity Monokine production by peritoneal exudate cells (PEC) was determined as follows: PEC were collected by a commonmethod1 5) from CNGtreated or non-treated tumor bearing mice (washing peritoneal cavity by ip injection of Hanks balanced salt solution (HBSS)) and incubated at 1 x 105 cells/ml in RPMI 1640 (Nissui Seiyaku Co. Ltd., Tokyo, Japan) containing 10% heat inactivated fetal calf serum at 37°C in 5% CO2 for 24 hours. After incubation, the culture supernatants were collected and the supernatants (100^I/well) and D10.G4.1 cells (1 x 104cells/well), were cultured with concanavalin A (Con A) 5 /ig/ml at 37°C in 5% CO2 for 3 days16).
[3H]TdR incorporation into Con A stimulated D10.G4.1. cells, which can grow in the presence of IL-117), was used for determination of monokine production by PEC. [3H]TdR was added (7.4 KBq/well) to cultures 16 hours before cell harvest, and monokine activity was determined by measuring the incorporation of [3H]TdR into the target cells. Triplicate cultures were made for each determination.
Production of lymphokines by splenic T cells was determined as follows: Splenic T cells (nylon wool passed cells) taken from tumor bearing mice given CNGwere suspended at 5 x 106cells/ml in RPMI 1640 supplemented 10% heat inactivated fetal calf serum, 50 fiM 2-mercaptoethanol, nonessential amino acids, l mMsodium pyruvate, 50 units/ml penicillin and 50/ig/ml streptomycin, and incubated at 37°C in 5% CO2for 3 days. CTLL-2and IC-2 cells were used for determination of lymphokine activities18'19*. The supernatants (100/d/well) and each cell suspension (1 x 104 cells/well) were cultured at 37°C in 5% CO2 for 2 days. The incorporation of [3H]TdRinto cells was measured as described above.
Statistical Analysis
Statistical significance was analyzed by Student's Mest.
Results
Antitumor effects of CNGat 0.5 or 5 mg/kg, doses which are effective in enhancing T cell activities in mice20), were examined against IMCcarcinoma in various schedules. As shown in Table 1, although administration of CNGdaily at 0.5 mg/kg and every 3rd day at 5 mg/kg had significant antitumor effects of 56 and 40% inhibition, respectively, weekly administration at 0.5 to 5 mg/kg inhibited the tumor growth by 47 to 66%. From these results, the antitumor effect of CNGwas hereafter examined by weekly administration. As shown in Fig. 1 , CNGat 0.05 to 5mg/kg exhibited significant antitimor effect but not at 50mg/kg did. The tumor growth during CNGtherapy is shown in Fig. 2 . CNGat 5 mg/kg significantly inhibited tumor growth on 21 to 35 days after tumor inoculation.
The antitumor effect ofCNGwas examined in mice treated with anti-asialo GM1serum and in athymic mice. As shownin Table 2 , in normal mice CNG showed antitumor effects but did not in those immunocompromised mice. In the course of CNGtherapy, CTL and NK activities, and cytokine production in tumor bearing mice were monitored every week for 4 weeks. As shown in Fig. 3 , CTL and NKactivities ofantitumor effector cells in tumor bearing mice were reduced in accordance with tumor growth, whereas those effector activities in mice given CNGwere maintained at normal levels. These activities were significant in late stages (21 to 28 days after tumor inoculation) of tumor growth.
Production of lymphokines by splenic T cells was determined by [3H]TdR incorporation into
cytokine dependent cell lines, CTLL-2 and IC-2 cells.
As shown in Fig. 4 , the culture supernatants markedly enhanced the incorporation of [3H]TdR into IL-2 dependent CTLL-2 and IL-3 dependent IC-2 cells in 21 and 28 days after tumor inoculation. On the other hand, monokine production by PECtaken from tumor-bearing mice without CNG increased gradually in accordance with tumor growth whereas it remained in the normal range in mice treated with CNGat 7, 14 and 21 days except at 28 days after tumor inoculation (7 days after the last administration of CNG).
Discussion
The influence of CNGon tumor growth, generation of antitumor effectors and cytokine production in tumor-bearing mice was investigated. Although the administration of CNGdaily or on every 3rd day inhibited tumor growth significantly, the most effective schedule in inhibiting tumor growth was weekly administration starting at day 1 or day 8 after tumor inoculation which exhibited a bell-shaped dose response (Fig. 1) . Since CNGdoes not show cytotoxicity to murine (IMC carcinoma, EL-4 thymona, P815 plasmacytoma) and human tumor cells (SC-6 stomach cancer, LX-1 lung cancer) at more than 100/ig/ml (unpublished data) and the antitumor activity was diminished in immunocompromised mice given anti-asialo GM1serum and in athymic mice, the antitumor activity of CNGcan be considered to be due to host mediated events. Thus, antitumor effectors and cytokine production in tumor-bearing mice given CNGwere monitored. After inoculation of tumor cells, CTLand NKactivities in non-treated mice were concomitantly enhanced for 2 weeks, thereafter, both activities were reduced in accordance with tumor growth, whereas in mice given CNG, CTL maintained high activity. Although NK activity was reduced slightly, it was higher than that of non-treated mice on days 21 and 28. Though the tumor cells were not sensitive to NK cells, conservation of NKactivity at a normal level in mice treated with CNGwould be a parameter which shows conservation of host defense mechanismsin the tumor-zbearing host. The culture supernatants of T cells taken from tumor-bearing mice given CNGenhanced the incorporation of [3H]TdR into CTLL-2 cells and IC-2 cells in late stage of tumor growth when the activity of antitumor effector cells such as CTL and NKcells appeared to be higher than those of non-treated mice. CTLL-2and IC-2 cells are used for assessment of lymphokine activities such as IL-2, IL-418'21) and IL-3, GM-CSF22), respectively. These results suggest that CNGstimulates T cells to produce lymphokines which act on generation of antitumor effector cells derived from T lineage cells such as CTL and NKcells in tumor bearing mice. In tumor-bearing mice, monokine production by PEC was gradually augmented in accordance with the tumor growth whereas CNGtreatment inhibited this augmentation and kept it in a normal range. It is known that inflammatory mediators, IL-1 , TGF-/?, TNF-a etc., are produced by activated macrophages, and IL-1 and cachectin/TNF-a may be mediators of cachexia23>24). Thus, it may be possible that CNG VOL.46 NO. ll THE JOURNAL OF ANTIBIOTICS 1697 prevents chronic inflammatory responses caused by macrophages, although CNGdoes not modulate monokine production by macrophages in vitro.
In this study, it is shown that a low molecular weight immunomodulatorCNGwhich stimulates activated T cells inhibits the growth of a syngeneic solid tumor in mice. CNGtherapy, weekly for 4 times starting 1 day after tumor inoculation, enhanced lymphokine production and generation of antitumor effector cells on days 21 and 28 in tumor-bearing mice. It prevented increase of monokine production by macrophages in accordance with tumor growth. Elsewhere, it will be reported that CNGstimulated T cells in bone marrowto produce megakaryocytes and improves the reduced platelet counts in peripheral blood of mice given cyclophosphamide25). A low molecular weight immunomodulator like CNGwhich stimulates activated T cells maybe useful for cancer treatment.
